ADEMPAS CAN BE TAKEN ALONE OR USED IN COMBINATION WITH ERAs OR PCAs FOR THE TREATMENT OF PAH (WHO GROUP 1)
Adempas can be taken alone or used in combination with medications called endothelin receptor antagonists (ERAs) or prostacyclin analogs (PCAs) (in inhaled, oral, or subcutaneous injection formulations) to treat pulmonary arterial hypertension (PAH) (WHO Group 1).
In a clinical trial, Adempas was studied in patients taking it by itself and also in combination with an ERA or PCA. Studies showed that Adempas may help your symptoms, even if you are being treated for PAH with an ERA or PCA. If you are taking these medications, your doctor may prescribe Adempas in addition to your current treatment to help your symptoms. If you are already taking an ERA or PCA and you would like to learn more about adding Adempas, talk to your doctor.
Do not take Adempas if you take certain other medicines that contain sildenafil (Revatio or Viagra), tadalafil (Adcirca or Cialis), vardenafil (Levitra or Staxyn), dipyridamole, or theophylline. Revatio and Adcirca are also used to treat PAH.
Do not take Adempas:
- Within 24 hours of sildenafil
- 24 hours before or within 48 hours after tadalafil
Talk to your doctor about other medications that can be taken with Adempas.
TREATMENTS FOR PAH TARGET DIFFERENT PATHWAYS
Adempas targets a different pathway than ERAs and PCAs to treat symptoms of PAH.
Adempas works with a chemical already in your body called sGC (soluble guanylate cyclase) to help keep blood vessels open and help more blood flow through your lung blood vessels. This happens within the NO-sGC-cGMP* pathway.
ERAs target a different pathway called the endothelin pathway. PCAs target a pathway called the prostacyclin pathway.
Your doctor may prescribe you treatments in one or more of these pathways.
ADEMPAS MAY HELP YOU WALK FARTHER EVEN IF YOU ARE TAKING AN ERA OR PCA FOR PAH
In a clinical study, patients with PAH who received Adempas and an ERA or PCA were able to walk farther (as measured by 6-minute walk distance) than patients who received placebo (an ERA or PCA without Adempas).
PATENT-1 was a 12-week clinical study that included 443 patients with PAH. About half of the patients had never been treated for PAH (50%; n=189/443), 44% (n=167/443) had been previously treated with an ERA, and 6% (n=27/443) had been previously treated with a PCA (inhaled, oral, or subcutaneous).
TALK TO YOUR DOCTOR ABOUT ADDING ADEMPAS
If you are already taking an ERA or PCA and you would like to learn more about adding Adempas, talk to your doctor.
For helpful tips on getting the most out of your conversations with your doctor and setting treatment goals, download the useful guide below and take it with you to your next visit.
Get tips for talking to your doctor